Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (139) and Ligand Pharmaceuticals (120). Figures as of 19 Nov 2026, 02:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.1
- Combined market value
- HUF 1700.08T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | HUF 22.84T | HUF 7,147.78 | 1.71% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 139 | HUF 114.14T | HUF 46,300.97 | 3.90% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | HUF 2.01T | HUF 100,381.50 | 1.67% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.7 | HUF 3.36T | HUF 22,219.63 | 5.44% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.2 | HUF 16.56T | HUF 14,191.39 | 0.92% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 73.3 | HUF 5.34T | HUF 83,263.11 | 2.93% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | HUF 2.51T | HUF 31,941.55 | 0.06% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.7 | HUF 2.56T | HUF 7,352.77 | 3.60% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.7 | HUF 15.49T | HUF 135,629.78 | 2.34% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.0 | HUF 2.49T | HUF 22,780.83 | 3.25% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.1 | HUF 169.89T | HUF 96,113.66 | 2.33% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 44.9 | HUF 13.27T | HUF 23,076.55 | 0.01% down | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 44.9 | HUF 413.91T | HUF 464,673.14 | 2.32% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.6 | HUF 10.56T | HUF 17,128.47 | 1.91% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | HUF 4.2T | HUF 5,034.03 | 1.28% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.4 | HUF 220.61T | HUF 91,640.84 | 2.15% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.1 | HUF 53.75T | HUF 9,429.56 | 1.44% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.0 | HUF 60.81T | HUF 35,110.50 | 0.22% down | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.5 | HUF 45.71T | HUF 180,274.02 | 0.42% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | HUF 98.51T | HUF 52,158.32 | 2.46% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | HUF 2.79T | HUF 42,732.12 | 2.00% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | HUF 93.17T | HUF 60,072.30 | 1.93% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.4 | HUF 38.02T | HUF 15,834.68 | 0.86% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.8 | HUF 8.26T | HUF 194,015.11 | 1.16% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | HUF 32.87T | HUF 317,745.36 | 1.28% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | HUF 5.96T | HUF 90,844.40 | 0.32% down | 28% up | ||
| 27 | GSKGSK · Health Care | 16.9 | HUF 32.72T | HUF 16,325.31 | 1.34% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.6 | HUF 11.68T | HUF 28,755.80 | 2.50% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.2 | HUF 40.91T | HUF 20,015.14 | 2.92% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | HUF 1.94T | HUF 2,846.34 | 1.85% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | HUF 58.4T | HUF 13,250.45 | 3.12% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | HUF 6.72T | HUF 50,205.87 | 4.54% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | HUF 1.52T | HUF 13,902.39 | 1.59% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 336.1 HUF). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (139) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 19 Nov 2026, 02:14 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of HUF 1700.08T as of 19 Nov 2026, 02:14 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.